NICE opts to reject Acorda’s MS drug Fampyra

Pharma Times

22 June 2022 - NICE has announced its decision to reject Fampyra – also known as fampridine – for use in England.

 The drug was developed by Acorda Therapeutics and is manufactured by Elan Corporation.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder